Participation of FLIP, RIP and Bcl-xL in fas-mediated T-cell death

被引:3
|
作者
Djerbi, M.
Malinowski, M. M.
Yagita, H.
Zhivotovsky, B.
Grandien, A.
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Infect Med, Dept Med, S-14186 Huddinge, Sweden
[2] Univ Stockholm, Wenner Gren Inst, Dept Immunol, S-11345 Stockholm, Sweden
[3] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
[4] Karolinska Inst, Inst Environm Med, Dept Toxicol, S-10401 Stockholm, Sweden
[5] Karolinska Univ Hosp, Karolinska Inst, Ctr Expt Hematol, Dept Med, Stockholm, Sweden
关键词
D O I
10.1111/j.1365-3083.2007.01957.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Apart from the conventional Fas signalling pathway, alternative pathways including the mitochondrial caspase-dependent and RIP-mediated cell death routes have been proposed to operate during Fas-mediated cell death. To evaluate the contribution of different Fas signalling pathways, mice overexpressing FLIPL, Bcl-x(L), a kinase-deficient form of RIP (RIP Delta kin) or combinations thereof were generated by retroviral gene transfer of haematopoietic stem cells. Such mice did not show overt abnormalities in haematopoietic development, defects in thymic deletion, accumulation of double-negative T cells or signs of autoimmunity. Fas-mediated death of mitogen-activated T cells was caspase dependent and could be blocked by FLIPL overexpression only with the minor involvement of Bcl-x(L) or RIP Delta kin inhibitable pathways. Fas-mediated death of resting CD4(+) and CD8(+) T cells was mainly caspase dependent but could only partly be blocked by FLIPL overexpression. Both Bcl-x(L) or RIP Delta kin expression resulted in partial protection of CD8(+) T cells against Fas-mediated cell death. These results indicate that yet uncharacterized signalling pathways from the Fas receptor are critically involved in lymphoproliferative and autoimmune disease observed in lpr mice and autoimmune lymphoproliferative syndrome patients.
引用
收藏
页码:410 / 421
页数:12
相关论文
共 50 条
  • [31] Bcl-XL induces apoptosis and susceptibility to CD95 (Fas)-mediated apoptosis in a B cell lymphoma cell line
    Omene, CO
    Lederman, SM
    FASEB JOURNAL, 1999, 13 (04): : A331 - A331
  • [32] Resistance to Fas-mediated T cell apoptosis in asthma
    Jayaraman, S
    Castro, M
    O'Sullivan, M
    Bragdon, MJ
    Holtzman, MJ
    JOURNAL OF IMMUNOLOGY, 1999, 162 (03): : 1717 - 1722
  • [33] Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy
    Comi, C
    Gaviani, P
    Leone, M
    Ferretti, M
    Castelli, L
    Mesturini, R
    Ubezio, G
    Chiocchetti, A
    Osio, M
    Muscia, F
    Bogliun, G
    Corso, G
    Gavazzi, A
    Mariani, C
    Cantello, R
    Monaco, F
    Dianzani, U
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2006, 11 (01) : 53 - 60
  • [34] Role of Fas-mediated cell death in the regulation of immune responses
    vanParijs, L
    Abbas, AK
    CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) : 355 - 361
  • [35] Superoxide anion is a natural inhibitor of Fas-mediated cell death
    Clement, MV
    Stamenkovic, I
    EMBO JOURNAL, 1996, 15 (02): : 216 - 225
  • [36] Mechanism of inhibition of Fas-mediated apoptosis by nitric oxide in a human T-cell line
    Ogura, T
    Tatemichi, M
    Esumi, H
    BIOLOGY OF NITRIC OXIDE, PT 7, 2000, 16 : 208 - 208
  • [37] Resistance of antigen-specific T cells to fas-mediated apoptosis induced by IL-12 antagonists is mediated by bcl-2 and bcl-xl.
    Marth, T
    Riing, S
    Schulte, D
    Zeitz, M
    GASTROENTEROLOGY, 2000, 118 (04) : A360 - A360
  • [38] PREVENTION OF HYPOXIA-INDUCED CELL-DEATH BY BCL-2 AND BCL-XL
    SHIMIZU, S
    EGUCHI, Y
    KOSAKA, H
    KAMIIKE, W
    MATSUDA, H
    TSUJIMOTO, Y
    NATURE, 1995, 374 (6525) : 811 - 813
  • [39] Degradation of Bcl-xL by DT2216 is lethal to T-cell acute lymphoblastic leukemia.
    Jaiswal, Arunima S.
    Williamson, Elizabeth
    Hromas, Robert A.
    Zhou, Daohong
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs
    Broome, HE
    Yu, AL
    Diccianni, M
    Camitta, BM
    Monia, BP
    Dean, NM
    LEUKEMIA RESEARCH, 2002, 26 (03) : 311 - 316